Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors
AUTOR(ES)
Mukherjee, Debabrata
FONTE
BioMed Central
RESUMO
Selective cyclooxygenase-2 (COX-2) inhibitors were developed to reduce the gastrointestinal toxicity of conventional nonsteroidal anti-inflammatory agents. However, COX-2 inhibitors decrease prostacyclin production and may disrupt the normal homeostatic balance, leading to a prothrombotic state and offsetting the potential gastrointestinal benefits. Available clinical data and basic biological studies raise significant concern about the potential prothrombotic effect of this class of drugs. Two recent studies with a newer, more selective COX-2 inhibitor have added to the already existing concern about the cardiovascular safety of these agents. The widespread use of these agents mandates prospective, randomized evaluation of the cardiovascular safety of COX-2 inhibitors.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=154429Documentos Relacionados
- COX-2: Where are we in 2003? - Specific cyclooxygenase-2 inhibitors and aspirin-exacerbated respiratory disease
- COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients
- COX-2: Where are we in 2003? - Distinction from NSAIDs becoming blurred
- Cox-2: Where are we in 2003? - The role of cyclooxygenase-2 in bone repair
- COX-2 inhibitors in the treatment of cardiovascular disease
